Portopulmonary Hypertension and Liver Transplant: Recent Review of the Literature


Creative Commons License

Cosarderelioglu C. , Cosar A. M. , Gurakar M., Pustavoitau A., Russell S. D. , Dagher N. N. , ...Daha Fazla

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, cilt.14, ss.113-120, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 14 Konu: 2
  • Basım Tarihi: 2016
  • Doi Numarası: 10.6002/ect.2015.0351
  • Dergi Adı: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
  • Sayfa Sayıları: ss.113-120

Özet

Portopulmonary hypertension is one of the main pulmonary conditions affecting patients with liver disease and/or portal hypertension. Other conditions include hepatopulmonary syndrome and hepatic hydrothorax. Portopulmonary hypertension is caused by pulmonary vasoconstriction and increased pulmonary vascular resistance. It develops as a result of portal hypertension with or without liver disease and is associated with a higher morbidity and mortality. However, portopulmonary hypertension is usually asymptomatic; the most common symptoms are dyspnea, fatigue, and peripheral edema. All liver transplant candidates should be screened for potential portopulmonary hypertension because its coexistence can affect survival rates after transplant. All patients with cirrhosis who present with dyspnea should also be screened. Transthoracic echo cardiography is a noni nvasive, useful method for screening, but right heart-sided catheterization remains the criterion standard for diagnosis. Portopulmonary hypertension carries a poor prognosis without liver transplant, and its severe form is considered to be a contraindication for liver transplant. Treating patients with pulmonary arterial hypertension-specific therapies before liver transplant for moderate and severe portopulmonary hyper tension appears to be beneficial.